Published in Lancet on August 29, 2008
Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2014) 2.21
Association of resting heart rate with carotid and aortic arterial stiffness: multi-ethnic study of atherosclerosis. Hypertension (2013) 2.18
Resting heart rate and risk of sudden cardiac death in the general population: influence of left ventricular systolic dysfunction and heart rate-modulating drugs. Heart Rhythm (2013) 1.56
Heart failure and Alzheimer's disease. J Intern Med (2014) 1.54
Chronotropic incompetence: causes, consequences, and management. Circulation (2011) 1.54
Exploring HCN channels as novel drug targets. Nat Rev Drug Discov (2011) 1.28
Low-conductance HCN1 ion channels augment the frequency response of rod and cone photoreceptors. J Neurosci (2009) 1.23
Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev (2009) 1.19
Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol (2013) 1.16
Heart rate, autonomic markers, and cardiac mortality. Heart Rhythm (2009) 1.11
Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol (2010) 1.08
Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness. Curr Cardiol Rev (2013) 1.07
Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol (2012) 1.04
Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol (2012) 1.02
Anxiety and depression lowers blood pressure: 22-year follow-up of the population based HUNT study, Norway. BMC Public Health (2011) 0.99
Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res (2009) 0.97
Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure. Ther Adv Drug Saf (2011) 0.95
Nocturnal nondipping of heart rate predicts cardiovascular events in hypertensive patients. J Hypertens (2009) 0.94
Biological Heart Rate Reduction Through Genetic Suppression of Gα(s) Protein in the Sinoatrial Node. J Am Heart Assoc (2012) 0.92
Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart Circ Physiol (2011) 0.92
Tachybradycardia in the isolated canine right atrium induced by chronic sympathetic stimulation and pacemaker current inhibition. Am J Physiol Heart Circ Physiol (2010) 0.92
The Contribution of HCN4 to normal sinus node function in humans and animal models. Pacing Clin Electrophysiol (2009) 0.90
Resting heart rate and risk of cardiovascular diseases and all-cause death: the Kailuan study. PLoS One (2014) 0.89
Heart rate is associated with red blood cell fatty acid concentration: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Am Heart J (2010) 0.89
Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One (2012) 0.89
Increased sympathetic nerve activity and reduced cardiac baroreflex sensitivity in rheumatoid arthritis. J Physiol (2016) 0.89
Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol (2009) 0.89
Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study. Clin Res Cardiol (2012) 0.88
Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol (2011) 0.88
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol (2011) 0.87
Management standards for stable coronary artery disease in India. Indian Heart J (2016) 0.86
Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol (2010) 0.86
Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. J Am Heart Assoc (2015) 0.85
Silencing of the Drosophila ortholog of SOX5 in heart leads to cardiac dysfunction as detected by optical coherence tomography. Hum Mol Genet (2013) 0.85
BEAUTIFUL results--the slower, the better? Lancet (2008) 0.84
Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias. J Mol Cell Cardiol (2013) 0.84
Heart rate differentiates urgency and emergency in hypertensive crisis. Clin Res Cardiol (2013) 0.83
[Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry]. Wien Klin Wochenschr (2011) 0.83
Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis. J Am Heart Assoc (2015) 0.83
Effect of an L- and T-type calcium channel blocker on 24-hour systolic blood pressure and heart rate in hypertensive patients. Korean Circ J (2012) 0.83
Drug therapy for heart failure in older patients-what do they want? J Geriatr Cardiol (2015) 0.82
Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther (2014) 0.82
Targeted ablation of cardiac sympathetic neurons reduces resting, reflex and exercise-induced sympathetic activation in conscious rats. Am J Physiol Heart Circ Physiol (2009) 0.82
A prospective population study of resting heart rate and peak oxygen uptake (the HUNT Study, Norway). PLoS One (2012) 0.82
Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS One (2014) 0.81
Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. Clin Res Cardiol (2016) 0.81
A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study. Respir Res (2012) 0.81
The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol (2012) 0.81
Treatment of Stable Angina Pectoris With Ivabradine in Everyday Practice: A Pan-Hellenic, Prospective, Noninterventional Study. Clin Cardiol (2015) 0.81
Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Des Devel Ther (2014) 0.81
Prognostic significance of heart rate in hospitalized patients presenting with myocardial infarction. World J Cardiol (2012) 0.81
A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One (2013) 0.81
Variation in resting heart rate over 4 years and the risks of myocardial infarction and death among older adults. Heart (2014) 0.80
A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure. Int J Pept (2012) 0.80
HCN channels--modulators of cardiac and neuronal excitability. Int J Mol Sci (2015) 0.80
Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation - a pilot study. Arch Med Sci (2012) 0.80
Fatty acids linked to cardiovascular mortality are associated with risk factors. Int J Circumpolar Health (2015) 0.79
Increased heart rate and atherosclerosis: potential implications of ivabradine therapy. World J Cardiol (2011) 0.79
Structure of the SthK carboxy-terminal region reveals a gating mechanism for cyclic nucleotide-modulated ion channels. PLoS One (2015) 0.79
Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol (2010) 0.78
Association between resting heart rate and cardiovascular mortality: evidence from a meta-analysis of prospective studies. Int J Clin Exp Med (2015) 0.78
Office and 24-hour heart rate and target organ damage in hypertensive patients. BMC Cardiovasc Disord (2012) 0.78
Prognostic value of resting heart rate on cardiovascular and renal outcomes in type 2 diabetic patients: a competing risk analysis in a prospective cohort. Diabetes Care (2012) 0.78
Combined effects of hypertension and heart rate on the risk of stroke and coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China. Hypertens Res (2015) 0.78
Association between resting heart rate across the life course and all-cause mortality: longitudinal findings from the Medical Research Council (MRC) National Survey of Health and Development (NSHD). J Epidemiol Community Health (2014) 0.77
Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol (2011) 0.77
Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand? Cardiovasc Ther (2013) 0.77
Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats. ScientificWorldJournal (2012) 0.77
Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate. Adv Ther (2015) 0.77
Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study. J Clin Hypertens (Greenwich) (2013) 0.77
Effectiveness and Tolerability of Ivabradine with or Without Concomitant Beta-Blocker Therapy in Patients with Chronic Stable Angina in Routine Clinical Practice. Adv Ther (2016) 0.77
Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure. Drugs (2013) 0.76
Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives. Clin Dev Immunol (2012) 0.76
Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol (2010) 0.76
Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008. Clin Res Cardiol (2008) 0.75
The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy. Front Pharmacol (2016) 0.75
Cardiovascular effects of incretin therapy in diabetes care. Metab Syndr Relat Disord (2014) 0.75
The BEAUTIFUL study: is heart rate reduction a new therapeutic principle? Curr Hypertens Rep (2009) 0.75
The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. Medicine (Baltimore) (2016) 0.75
Chronic Treatment with Ivabradine Does Not Affect Cardiovascular Autonomic Control in Rats. Front Physiol (2016) 0.75
Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. Int J Obes (Lond) (2014) 0.75
Advances in the management of heart failure: the role of ivabradine. Vasc Health Risk Manag (2016) 0.75
Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol (2014) 0.75
Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena? Indian Pacing Electrophysiol J (2009) 0.75
Short-term effects of ivabradine in patients with chronic stable ischemic heart disease. Heart Views (2013) 0.75
Resting heart rate in patients with ischemic heart disease in Saudi Arabia and Egypt. J Saudi Heart Assoc (2011) 0.75
Secondary prevention following myocardial infarction--there is still more to be done. Dtsch Arztebl Int (2011) 0.75
Pulsatility Index as a Diagnostic Parameter of Reciprocating Wall Shear Stress Parameters in Physiological Pulsating Waveforms. PLoS One (2016) 0.75
Evaluation of heart rate measurements in clinical studies: a prospective cohort study in patients with heart disease. Eur J Clin Pharmacol (2016) 0.75
Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats. J Vet Cardiol (2011) 0.75
Dysfunctional Hyperpolarization-Activated Cyclic Nucleotide-gated Ion Channels in Cardiac Diseases. Braz J Cardiovasc Surg (2016) 0.75
Benefit of heart rate reduction in heart failure. Curr Heart Fail Rep (2010) 0.75
Adult ADHD Medications and Their Cardiovascular Implications. Case Rep Cardiol (2016) 0.75
Heartbeat Cycle Length Detection by a Ballistocardiographic Sensor in Atrial Fibrillation and Sinus Rhythm. Biomed Res Int (2015) 0.75
Heart rate and cardiovascular disease: an alternative to Beta blockers. Cardiol Res Pract (2009) 0.75
Upregulation of M₃ muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II. J Transl Med (2013) 0.75
The Effect of Face-to-Face Education and Educational Booklet on Heart Health Indexes of the Hospitalized Patients with Myocardial Infarction. Nurs Res Pract (2013) 0.75
Management Protocols of stable coronary artery disease in India: Executive summary. Indian Heart J (2016) 0.75
The Effects of Ivabradine on Left Ventricular Synchronization and Tei Index in Patients with Systolic Heart Failure. Acta Cardiol Sin (2017) 0.75
The predictive value of resting heart rate following osmotherapy in brain injury: back to basics. Daru (2012) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet (2007) 6.57
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol (2011) 5.46
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation (2012) 4.09
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation (2003) 3.75
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J (2004) 3.27
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Outcomes of elective induction of labour compared with expectant management: population based study. BMJ (2012) 3.07
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Potential impact of public access defibrillators on survival after out of hospital cardiopulmonary arrest: retrospective cohort study. BMJ (2002) 2.89
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA (2005) 2.74
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens (2010) 2.73
Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail (2013) 2.73
Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail (2012) 2.72
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med (2008) 2.61
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med (2010) 2.52
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol (2005) 2.43
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol (2011) 2.39
Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med (2013) 2.37
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30